Konsyl Pharmaceuticals to Supply Laxative for New Xyralid™ RC Hemmorhoid Kit

Konsyl Pharmaceuticals, Inc. a leading producer of high quality, natural supplements, has entered a supplier agreement to provide Auriga Laboratories, Inc. with their Konsyl® Original formula for their new complete hemorrhoid care kit.

Easton, MD (PRWEB) July 18, 2007

Konsyl Pharmaceuticals, Inc. a leading producer of high quality, natural supplements, has entered a supplier agreement to provide Auriga Laboratories, Inc. with their Konsyl® Original formula for their new complete hemorrhoid care kit. The new prescription kit, Xyralid™ RC contains a prescription ointment and wipes as well as Konsyl® Natural Bulk-Forming Laxative.

Konsyl® Natural Bulk-Forming Laxative, unlike other products that contain fillers or artificial sweeteners, contains 100% psyllium. Konsyl® utilizes the psyllium husk - the most hydrophilic part of the psyllium plant. Each teaspoon dose contains 6.0 grams of psyllium, providing more fiber per dose than any other bowel normalizer. Konsyl contains no sugar, sugar substitutes, or any other additives. It is an excellent stool softener, is very low in sodium, requires fewer daily doses, only contains 3 calories per dose and is safe for pregnant women and diabetics.

Konsyl Pharmaceuticals, Inc. is a manufacturer and distributor of high quality, natural fiber supplements for improved intestinal and digestive health. Konsyl Pharmaceuticals is a subsidiary of ICC Industries Inc., a New York-based global leader in manufacturing, marketing and trading chemicals, pharmaceuticals and plastics. The high fiber content of Konsyl products helps consumers to achieve dependable intestinal health. Konsyl fiber products are available in fine pharmacies and chain stores throughout the United States. For more information on Konsyl Pharmaceuticals, Inc. or its complete line of products, contact a company representative at 800-356-6795, or visit the company's website at http://www.konsyl.com.

Auriga Laboratories, Inc. (OTCBB:ARGA), is a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl®, and Levall® families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: http://www.aurigalabs.com.

###


Contact